Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 353

1.

Foxp3 expression in melanoma cells as a possible mechanism of resistance to immune destruction.

Niu J, Jiang C, Li C, Liu L, Li K, Jian Z, Gao T.

Cancer Immunol Immunother. 2011 Aug;60(8):1109-18. doi: 10.1007/s00262-011-1025-3. Epub 2011 May 6.

PMID:
21547596
2.

Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human.

Kang N, Tang L, Li X, Wu D, Li W, Chen X, Cui L, Ba D, He W.

Immunol Lett. 2009 Aug 15;125(2):105-13. doi: 10.1016/j.imlet.2009.06.005. Epub 2009 Jun 17.

PMID:
19539651
3.

[Effect of human bone marrow mesenchymal stem cells on allogeneic regulatory T cells and its possible mechanism].

Yang J, Wang QH, Zeng QT, Mao XB.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Aug;15(4):785-9. Chinese.

PMID:
17708804
4.

Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression.

Strauss L, Bergmann C, Szczepanski MJ, Lang S, Kirkwood JM, Whiteside TL.

J Immunol. 2008 Mar 1;180(5):2967-80.

5.

[Inhibitory effect of lentiviral-mediated RNA on the expression of Foxp3 protein in melanoma cells].

Chen DJ, Li XS, Zhao H, Shi XL, Zhang HH, Fan ZY, Yao YM, DU N.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2012 Apr;28(4):337-9. Chinese.

PMID:
22482399
6.
7.

CD4(+) CD25(low) GITR(+) cells: a novel human CD4(+) T-cell population with regulatory activity.

Bianchini R, Bistoni O, Alunno A, Petrillo MG, Ronchetti S, Sportoletti P, Bocci EB, Nocentini G, Gerli R, Riccardi C.

Eur J Immunol. 2011 Aug;41(8):2269-78. doi: 10.1002/eji.201040943. Epub 2011 Jul 4.

8.

Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer.

Hinz S, Pagerols-Raluy L, Oberg HH, Ammerpohl O, Grüssel S, Sipos B, Grützmann R, Pilarsky C, Ungefroren H, Saeger HD, Klöppel G, Kabelitz D, Kalthoff H.

Cancer Res. 2007 Sep 1;67(17):8344-50.

9.

Point mutants of forkhead box P3 that cause immune dysregulation, polyendocrinopathy, enteropathy, X-linked have diverse abilities to reprogram T cells into regulatory T cells.

McMurchy AN, Gillies J, Allan SE, Passerini L, Gambineri E, Roncarolo MG, Bacchetta R, Levings MK.

J Allergy Clin Immunol. 2010 Dec;126(6):1242-51. doi: 10.1016/j.jaci.2010.09.001. Epub 2010 Oct 30.

PMID:
21036387
10.

Correlation between the degree of immune activation, production of IL-2 and FOXP3 expression in CD4+CD25+ T regulatory cells in HIV-1 infected persons under HAART.

Terzieva V, Popova D, Kicheva M, Todorova Y, Markova R, Martinova F, Elenkov I, Yankova M.

Int Immunopharmacol. 2009 Jul;9(7-8):831-6. doi: 10.1016/j.intimp.2009.03.009. Epub 2009 Mar 18.

PMID:
19303058
11.

Aurintricarboxylic acid promotes the conversion of naive CD4+CD25- T cells into Foxp3-expressing regulatory T cells.

Lim DG, Park YH, Kim SE, Kim YH, Park CS, Kim SC, Park CG, Han DJ.

Int Immunol. 2011 Sep;23(9):583-92. doi: 10.1093/intimm/dxr058. Epub 2011 Jul 12.

12.

Forced overexpression of either of the two common human Foxp3 isoforms can induce regulatory T cells from CD4(+)CD25(-) cells.

Aarts-Riemens T, Emmelot ME, Verdonck LF, Mutis T.

Eur J Immunol. 2008 May;38(5):1381-90. doi: 10.1002/eji.200737590.

13.
14.

Stimulation of α7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro.

Wang DW, Zhou RB, Yao YM, Zhu XM, Yin YM, Zhao GJ, Dong N, Sheng ZY.

J Pharmacol Exp Ther. 2010 Dec;335(3):553-61. doi: 10.1124/jpet.110.169961. Epub 2010 Sep 15.

15.

Absence of amplification of CD4+CD25(high) regulatory T cells during in vitro expansion of tumor-infiltrating lymphocytes in melanoma patients.

Knol AC, Lemaître F, Pandolfino MC, Volteau C, Quéreux G, Saiagh S, Khammari A, Viguier M, Dréno B.

Exp Dermatol. 2008 May;17(5):436-45. doi: 10.1111/j.1600-0625.2007.00681.x. Epub 2008 Feb 27.

PMID:
18312383
16.

TGF-beta1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets.

Pyzik M, Piccirillo CA.

J Leukoc Biol. 2007 Aug;82(2):335-46. Epub 2007 May 2.

17.

Immune compartmentalization of T cell subsets in chemically-induced breast cancer.

Fahmi T, Esendagli G, Yilmaz G, Kansu E, Guc D.

Scand J Immunol. 2010 Oct;72(4):339-48. doi: 10.1111/j.1365-3083.2010.02447.x.

18.

Deficient SOCS3 expression in CD4+CD25+FoxP3+ regulatory T cells and SOCS3-mediated suppression of Treg function.

Pillemer BB, Xu H, Oriss TB, Qi Z, Ray A.

Eur J Immunol. 2007 Aug;37(8):2082-9.

19.

Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity.

Pallandre JR, Brillard E, Créhange G, Radlovic A, Remy-Martin JP, Saas P, Rohrlich PS, Pivot X, Ling X, Tiberghien P, Borg C.

J Immunol. 2007 Dec 1;179(11):7593-604.

20.

Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells.

Martin-Orozco N, Li Y, Wang Y, Liu S, Hwu P, Liu YJ, Dong C, Radvanyi L.

Cancer Res. 2010 Dec 1;70(23):9581-90. doi: 10.1158/0008-5472.CAN-10-1379. Epub 2010 Nov 23.

Items per page

Supplemental Content

Write to the Help Desk